Position in LLY
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$63,464
+$9,730 QoQ
Shares Held
69
+38.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Tidemark, LLC holds $1,577,195 across 14 Drug Manufacturers - General names. LLY ranks #7 (4.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
8,366 | $507,397 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
3,023 | $421,315 | |
| 3 | JNJ |
Johnson & Johnson
|
1,053 | $257,395 | |
| 4 | BIIB |
Biogen Inc.
|
593 | $108,714 | |
| 5 | ABBV |
AbbVie Inc.
|
331 | $71,989 | |
| 6 | PFE |
Pfizer Inc
|
2,492 | $69,975 | |
| 7 | LLY |
ELI LILLY & Co
This page
|
69 | $63,464 | |
| 8 | NVO |
Novo Nordisk A S
|
747 | $27,452 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $63,464 | 69 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $53,734 | 50 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $41,965 | 55 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $39,756 | 51 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $24,777 | 30 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $42,460 | 55 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $44,297 | 50 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $45,269 | 50 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $38,898 | 50 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $29,146 | 50 | Shares | Sole | 2024-02-09 | |
| No filing history on record for this holder in this stock. | ||||||